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ABSTRACT
Introduction: Postoperative atrial fibrillation (AF) occurs
in 30–40% of patients after cardiac surgery. Identification
of recurrent postoperative AF is required to initiate
evidence-based management to reduce the risk of
subsequent stroke. However, as AF is often
asymptomatic, recurrences may not be detected after
discharge. This study determines feasibility and impact of
a self-surveillance programme to identify recurrence of
postoperative AF in the month of posthospital discharge.
Methods and analysis: This is a feasibility study,
using a cross-sectional study design, of self-screening
for AF using a hand-held single-lead iPhone
electrocardiograph device (iECG). Participants will be
recruited from the cardiothoracic surgery wards of the
Royal North Shore Hospital and North Shore Private
Hospital, Sydney, Australia. Cardiac surgery patients
admitted in sinus rhythm and experiencing a transient
episode of postoperative AF will be eligible for
recruitment. Participants will be taught to take daily ECG
recordings for 1 month posthospital discharge using
the iECG and will be provided education regarding AF,
including symptoms and health risks. The primary
outcome is the feasibility of patient self-monitoring for
AF recurrence using an iECG. Secondary outcomes
include proportion of patients identified with recurrent
AF; estimation of stroke risk and patient knowledge.
Process outcomes and qualitative data related to
acceptability of patient’s use of the iECG and
sustainability of the screening programme beyond the
trial setting will also be collected.
Ethics and dissemination: Primary ethics approval
was received on 25 February 2014 from Northern
Sydney Local Health District Human Resource Ethics
Committee, and on 17 July 2014 from North Shore
Private Hospital Ethics Committee. Results will be
disseminated via forums including, but not limited to,
peer-reviewed publications and presentation at national
and international conferences.
Trial registration number: ACTRN12614000383662.
INTRODUCTION
Atrial ﬁbrillation (AF) is one of the most
common cardiac events following cardiac
surgery, occurring in 30–40% of patients.1 2
The incidence of postoperative AF is pre-
dicted to increase as the population ages and
increased numbers of elderly people undergo
cardiac surgery.3 Postoperative AF increases
the risk of inhospital mortality, prolongs
length of stay, and postdischarge increases
costs and complications, such as stroke, renal
failure and gastrointestinal complications.4
While new onset postoperative AF is generally
considered to be transient and reversible,1 5 it
may recur in up to 8% of patients in the
2 years following surgery, with an annual inci-
dence of 2%.6 7 This is a likely underestimate
of the actual rate due to asymptomatic AF and
lack of routine surveillance.7 As postoperative
AF is an independent predictor of worse long-
term outcomes, including stroke and
death,4 5 8 surveillance for recurrence of AF
and routine screening for AF-related compli-
cations should occur postdischarge in any
patient who experiences postoperative AF
and is at risk of recurrent AF.8 Increased risk
is associated with patient’s age over 65 years,
Strengths and limitations of this study
▪ This study investigates the novel concept of edu-
cating patients to undertake self-surveillance for
recurrence of postoperative atrial fibrillation.
▪ The main strength of this study is that it utilises
innovative technology to screen for atrial fibrilla-
tion, which is non-invasive, quick and easy for
the patient to use. The single-lead ECG recording
is interpreted by a validated automated algorithm
and is available for immediate review by a health
professional remotely.
▪ This is a feasibility study and therefore, the
results will determine the feasibility of patient
self-monitoring, and inform the design and
refinement of a future large-scale intervention
and implementation study.
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and modestly with valve surgery, and prior heart failure
and hypertension.3 However, in current practice, the
everyday surveillance for recurrence of postoperative AF
largely falls on the patients themselves.
There is little published information on patients’ under-
standing and knowledge of AF, and their capacity to under-
take such surveillance postcardiac surgery. Previous surveys
have demonstrated that people with AF have poor knowl-
edge of AF and the related symptoms, and are generally
unaware or not concerned with their elevated risk of
stroke.9–11 Patients’ education, which is individualised, has
been demonstrated in a systematic review to produce most
beneﬁts for patient’s self-care capability12 and thereby
reduces complications and readmissions.13 No study was
found that reported techniques to improve patient’s cap-
ability to provide self-care following postoperative AF.
New technology that is portable, quick and easy to use
increases the capability of individuals to undertake sur-
veillance postdischarge. Utilising an iPhone-based 30 s
single-lead ECG, the AliveCor heart monitor (iECG;
ﬁgure 1), we have been able to successfully identify previ-
ously undetected AF in 1.5% of ambulatory community
residents aged ≥65 years.14 The iECG has a validated
automatic algorithm for detection of AF15 which, when
used in the ﬁeld, maintains a high sensitivity (98.5%) and
speciﬁcity (91.4%).14 The algorithm provides an immedi-
ate automated interpretation of the ECG which is avail-
able to the treating doctors in real time through a secure
server. Under the direction of a healthcare professional,
it is possible that patients could use this technology in the
postdischarge period to monitor for recurrence of AF.
STUDY AIMS
This study aims to:
1. Determine the feasibility of patients using an iECG to
identify recurrence of AF in the early postdischarge
period (i.e, 4 weeks postdischarge) following cardio-
thoracic surgery;
2. Determine if providing a brief inpatient AF education
programme improves patient knowledge;
3. Explore the experience of the participant in using
the iECG in the home setting, and acceptability of
the intervention;
4. Inform the development of a future larger scale trial.
METHODS AND ANALYSIS
Design
This study is a feasibility study, using a cross-sectional
study design, of monitoring to detect the recurrence of
AF postdischarge from hospital (ﬁgure 2;
ACTRN12614000383662). We also use a prepost study
design to evaluate a brief educational module on AF.
The study period is from 25 March 2014 until 28 April
2015. The intervention will be offered at two hospital
sites in Sydney, Australia: The Royal North Shore
Hospital and The North Shore Private Hospital.
Recruitment will occur between 25 March 2014 to 28
March 2015 at The Royal North Shore Hospital and
between 4 August 2014 to 28 March 2015 at The North
Shore Private Hospital.
Study population
All cardiothoracic surgery patients who were admitted to
hospital in stable sinus rhythm and subsequently experi-
enced postoperative AF following cardiac surgery, and
who reverted or were cardioverted to sinus rhythm prior
to discharge. Patients must be able to provide informed
consent and be ≥18 years old. Patients will be excluded
if they are non-English speaking or have insufﬁcient cog-
nitive capacity for the consent and interview process or
are not returning home or are unable to be contacted
via telephone in the postdischarge period.
Enrolment and randomisation procedures
Potential participants will be identiﬁed from the cardio-
thoracic wards by the ward staff in consultation with the
research assistant. The research assistant will assess eligi-
bility against the inclusion/exclusion criteria, and
approach all eligible participants during their inpatient
stay. The research study and the commitment involved
will be clearly described in lay terms. Potential partici-
pants will be afforded every opportunity to ask questions
about the study without prejudice, and to choose
whether or not to participate. Participation in the study
is entirely voluntary and choosing not to participate will
not in any way affect any future treatment. There are no
rewards or incentives for participation in the study. The
participant will be enrolled into the study after the
informed consent process has been completed. As this is
Figure 1 AliveCor heart monitor.
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a pre–post study and all participants will receive the
intervention, there will be no randomisation and the
study will not be blinded.
Baseline assessment
The baseline assessment will be performed during the
inpatient stay. Sociodemographic and clinical data will
be collected from the medical record and the
participant.
Assessment measures:
1. Demographic data: age, gender, education level.
2. Medical history:
▸ Data on admission for surgical procedure(s), pre-
operative left ventricular function and comorbid-
ities, including thyroid function/status, obstructive
sleep apnoea and pulmonary disease, will be
collected.
▸ Calculation of stroke risk using CHA2DS2-VASc
score.16
▸ Postoperative complications assessed according to
major adverse cardiac events (MACE).17
3. AF knowledge: using a modiﬁed version of the Atrial
Fibrillation Knowledge Scale18 (permission for modi-
ﬁcation obtained from original authors; see online
supplement 1).
4. A 30 s lead-1 ECG to determine baseline heart
rhythm: assessed using the iECG.
Intervention
During their inpatient stay, participants will receive brief
individualised education regarding AF and its health
risks speciﬁcally in relation to stroke. Participants will be
educated regarding the spectrum of AF symptoms and
the need to monitor and discuss any symptoms with
their doctors or treating healthcare professionals.
Additionally, participants will be provided with AF educa-
tional material from the Atrial Fibrillation Association
(http://www.atrialﬁbrillation-au.org) to take home. All
participants will be provided with an iPhone and the
AliveCor Heart monitor (iECG) for the duration of the
study period. Participants will be taught how to record
their own 30 s ECG recording using the iECG and
shown how to complete the symptom diary.
Postdischarge from hospital, participants will be asked
to record an iECG four times per day for 4 weeks.
Participants will be advised to take additional iECG
recordings, as soon as practicable, if they experience AF
symptoms. Each iECG automatically transmits to a
secure server where each recording will be analysed by a
previously validated automated AF algorithm.15 All iECG
data on the server are coded for each participant and
therefore, are not identiﬁable. The research assistant
will review each iECG and the algorithm diagnosis, and
all ECG’s with suspected AF will be over-read by a cardi-
ologist from the research team. If AF, or any other clinic-
ally signiﬁcant event is identiﬁed, the research assistant
will contact the participant to arrange for urgent
follow-up with their treating doctors, and will advise the
treating doctors and specialists of the ﬁndings.
Participants will also be asked to keep an AF symptom
diary for 4 weeks. They will be asked to self-report on
the occurrence of any AF-related symptoms including
palpitations, dizziness and syncope and any medical or
hospital presentation related to these.
Follow-up assessment
A follow-up assessment will be performed 4 weeks post-
hospital discharge, either in the participant’s home or
in the outpatient clinic. The research assistant will
reassess the MACE and AF Knowledge Scale. The
research assistant will also compare the 4 weeks of iECG
readings with the AF symptom checklist and discuss the
results with the participant. On completion, a letter sum-
marising the participant’s speciﬁc outcomes will be sent
to their treating doctors. The participant will also be
invited to participate in a process evaluation interview
(as outlined in Process Measures) to explore their
experience using the iECG and factors related to future
sustainability.
Study outcomes
Primary outcome
Feasibility of patient self-monitoring for AF recurrence
using an iECG. Assessment measures include:
▸ Acceptability and patient’s willingness to participate
in the programme (measured using recruitment data
Figure 2 Study flow. AF, atrial fibrillation; iECG, iPhone
ECG.
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including the reasons provided for non-
participation);
▸ Participants’ ability to learn to use the iECG technol-
ogy and successfully take their own recordings;
▸ The compliance of participants to the intervention
(measured by the number of iECG recordings they
record over the 1 month, that is, are they achieving the
requested target of three to four recordings each day);
▸ The ability of the iECG to identify recurrences of AF
(measured using data from each participant obtained
from the iECG—reviewed for the presence of AF by
the research assistant and the automated algorithm).
Secondary outcomes
1. The proportion of patients identiﬁed with recurrent AF.
2. Patient knowledge of AF (measured using a modiﬁed
version of the Atrial Fibrillation Knowledge Scale).
3. Estimation of stroke risk of the participants identiﬁed
with recurrent AF (using CHA2DS2-VASc score).
4. Qualitative data regarding acceptability of patient use
of the iECG.
Process measures
A detailed process evaluation will be undertaken to
better appreciate factors that might inﬂuence sustain-
ability beyond the trial setting. After each participant
completes the programme, a process evaluation will be
performed related to participant’s experiences with the
iECG. Semistructured interviews will be conducted
addressing the ease of use of the iECG, and the beneﬁts
and challenges of the programme. The process evalu-
ation interview will be audio taped to ensure accurate
transcription of the information, with the written
consent of the participant. The audio recording will be
transcribed verbatim in a non-identiﬁable form and the
recording deleted.
Statistical considerations
Primary analyses will be conducted using SPSS for
Windows (V.19.0). New episodes of AF will be expressed
as true positives divided by total number screened with
accompanying 95% CIs. χ2 tests will be used to compare
new cases by gender and to identify associations between
AF incidence and age-group or AF risk factors. AF knowl-
edge level will be compared preintervention and postin-
tervention using paired t tests. Continuous variables will
be reported as means± SDs, and categorical variables as
numbers and percentages. Within subject differences
between baseline and follow-up will be analysed using
Wilcoxon signed ranks tests for non-parametric variables
(two tailed p<0.05 considered signiﬁcant).
As the primary outcome is feasibility and acceptability,
a power calculation was not performed. A sample size of
50 participants was chosen to maximise the probability
of reaching data saturation during thematic analysis of
the interviews and during review of process measures
such as reasons for declining participation. Analysis will
be limited to complete cases to avoid artiﬁcially
increasing precision around the estimates by imputing
values or carrying baseline values forward. As the study
is a pilot study, no interim analyses are anticipated.
Interview data will be transcribed verbatim and analysed
using general interpretive methods.19 Transcripts will be
reviewed independently for general themes by two
researchers and consensus reached.
ETHICS AND DISSEMINATION
National Health and Medical Research Council ethical
guidelines for human research will be adhered to, and
written and informed consent will be obtained from all
participants. The Anzac Research Institute will adminis-
ter the study. Implementation and conduct of the study
will be monitored by the project management commit-
tee (authors) who have extensive experience in qualita-
tive research and conducting clinical trials in
cardiovascular disease. The results of this study will be
disseminated via the usual scientiﬁc forums, including
peer-reviewed publications and presentations at inter-
national conferences.
CONCLUSIONS
Postoperative AF is thought to be mainly transient and
reversible. Research suggests it affects up to 8% of
patients in the 2 years following surgery; however, this is
a likely underestimate of the actual rate due to asymp-
tomatic AF and lack of routine surveillance. This obser-
vational study aims to determine the feasibility and
impact of self-screening using innovative technology in
the postdischarge period for people who have had a
transient postoperative episode of AF after cardiac
surgery. The study also aims to explore the effectiveness
of providing brief AF education during the inpatient
stay. The study will inform the design and reﬁnement of
a future intervention for large-scale research and
implementation.
We anticipate this study will demonstrate that it is pos-
sible to identify recurrence of paroxysmal AF in the post-
discharge period. Early identiﬁcation of AF recurrence
will reduce the risk of stroke and ultimately reduce
stroke burden.
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